Phase 2 Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People with a life expectancy of more than 12 weeks
- People with a good general level of physical functioning (rated 0 or 1 on a standard medical scale, meaning able to carry out normal daily activities with little or no restriction)
- People who have at least one area of disease that can be measured on a scan at the start of the trial
- For groups 1–4 only: People with a confirmed advanced or spreading solid tumour that has worsened after standard treatment, where standard treatment was not tolerated, where the person declined standard treatment, or where no standard treatment exists
- For groups 5 and 6 only: People with confirmed stage III (cannot be surgically removed) or stage IV melanoma who have previously tried one type of immunotherapy treatment (anti-PD-1/PD-L1) that did not work, and — if their melanoma has a specific gene change called BRAF V600 — have also previously tried a targeted therapy for that gene change
- For group 5 only: People aged 12 years or older at the time of giving consent
- For group 6 only: People aged 18 years or older at the time of giving consent
Who may not be able to join:
- People who have not fully recovered from a previous surgery or radiation therapy, including any ongoing side effects from radiation, or who still need steroid medicines as a result
- People who are pregnant, breastfeeding, or planning to become pregnant during the study treatment or within three months after the last dose of the study drug
- People with a known history of HIV (HIV 1/2)
- For groups 5 and 6 only: People who have another cancer that is actively growing or being treated
- For groups 5 and 6 only: People with a type of eye-related melanoma called uveal or ocular melanoma
- For groups 5 and 6 only: People with active cancer spread to the brain or the lining around the brain or spinal cord
- For groups 5 and 6 only: People who have already received more than two rounds of systemic (whole-body) treatment for unresectable or metastatic melanoma
- For groups 5 and 6 only: People who had to permanently stop anti-LAG-3 or anti-PD-1 immunotherapy in the past because it caused intolerable side effects
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: David Chien, MD, Senior Vice President of Clinical Development
Phone: 412-586-5830
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of adverse events (AEs); Percentage of serious adverse events (SAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.